HIGHLIGHTS
- who: Plumas, and RD, from the PDC*line Pharma, Grenoble, France have published the research work: Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines, in the Journal: (JOURNAL)
- what: NeoAgs appear attractive candidates to induce specific anti-tumor responses in cancer patients, on top of classical tumor-associated antigens and in association with ICIs.
SUMMARY
Combination of ICIs with therapeutic cancer vaccines that aimed at priming or enhancing anti-tumor CD8+ T-cell effectors could increase the efficacy of each treatment used separately. Neoantigens as a source . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.